Cannabinoid therapy in epilepsy

Billakota, Santoshi; Devinsky, Orrin; Marsh, Eric D.

doi:10.1097/wco.0000000000000660

Cited by 63 publications

(45 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties across many neuropsychiatric disorders. 8 Indeed, Epidiolex Ò (99% CBD; 0.1% D-9-tetrahydrocannabinol [THC]) has been approved in some places for the treatment of epilepsy 9 and clinical trials have established that CBD can be an effective treatment for pediatric epilepsy, 10,11 or epilepsy with a pediatric onset. 12,13 Interest in the broader therapeutic potential of CBD is exemplified by the burgeoning number of systematic reviews and meta-analyses published within the past few years that champion its use in a number of potential therapeutic indications.…”

Section: Introductionmentioning

confidence: 99%

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence

Wright

Ciano

Brands

2020

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as the majority of existing data suggest it is safe, well tolerated, has few adverse effects, and demonstrates no potential for abuse or dependence in humans. Pre-clinical research using animal models of innate fear and anxiety-like behaviors have found anxiolytic, antistress, anticompulsive, and panicolytic-like effects of CBD. Preliminary evidence from human trials using both healthy volunteers and individuals with social anxiety disorder, suggests that CBD may have anxiolytic effects. Although these findings are promising, future research is warranted to determine the efficacy of CBD in other anxiety disorders, establish appropriate doses, and determine its long-term efficacy. The majority of pre-clinical and clinical research has been conducted using males only. Among individuals with anxiety disorders, the prevalence rates, symptomology, and treatment response differ between males and females. Thus, future research should focus on this area due to the lack of research in females and the knowledge gap on sex and gender differences in the effectiveness of CBD as a potential treatment for anxiety.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence

Wright

Ciano

Brands

2020

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

show abstract

“…CBD is devoid of abuse potential given its lack of rewarding effects [ 20 – 22 ]. It also has a favourable safety profile and was recently approved for the treatment of rare childhood seizure disorders [ 23 , 24 ]. This makes CBD an attractive candidate therapeutic for treating anxiety-related disorders.…”

Section: Phytocannabinoid Regulation Of Fear and Anxiety: The Case Fomentioning

confidence: 99%

Cannabinoid Regulation of Fear and Anxiety: an Update

Papagianni

Stevenson

2019

Curr Psychiatry Rep

View full text Add to dashboard Cite

Purpose of Review Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings Evidence from preclinical studies has shown that the non-psychotropic phytocannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear by dampening its expression, enhancing its extinction and disrupting its reconsolidation. The findings from the relevant clinical literature are still very preliminary but are nonetheless encouraging. Summary Based on this preclinical evidence, larger-scale placebo-controlled clinical studies are warranted to investigate the effects of cannabidiol in particular as an adjunct to psychological therapy or medication to determine its potential utility for treating anxiety-related disorders in the future.

show abstract

“…In fact, direct CB 1 receptor agonists may even induce or aggravate epileptic seizures, depending on the dose (Asth et al, 2019). CBD, on the other hand, has been demonstrated to be efficacious in reducing epileptic seizures in both experimental and clinical settings (Billakota et al, 2019). Contrary to THC, CBD does not act as a CB 1 receptor agonist; instead, its antiepileptic activity seems to occur by inhibiting anandamide reuptake and hydrolysis, increasing the brain levels of this endocannabinoid and thereby activating CB 1 receptor signaling (Vilela et al, 2013).…”

Section: Cannabinoids and The Endocannabinoid Systemmentioning

confidence: 99%